ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Jul 28, 2017
Altria Keeps Smoking; Is Smokeless the Future for Big Tobacco?
Tobacco giant Altria reported another solid quarter thanks in large part to its pricing power, but big tobacco may be altering its strategy as it finds an unexpected ally.
Jul 27, 2017
Hasbro Hit by Gross Margin, Timing Issues
Shares of Dividend Growth Newsletter portfolio holding Hasbro dropped after the company reported its second quarter earnings. We're watching shares closely.
Jul 26, 2017
Boeing’s Shares Rocketing Higher
Image Source: Rob Bulmahn. Dividend Growth Newsletter portfolio holding Boeing issued second-quarter results and raised full-year 2017 guidance. We remain bullish on the commercial aerospace supply chain and defense contractors amid increasing geopolitical tensions across the globe.
Jul 25, 2017
Stocks in the News: Kinder Morgan, Union Pacific, Colgate-Palmolive
Let’s cover the quarterly reports from a few industry bellwethers.
Jul 21, 2017
Stocks in the News: Visa, Microsoft, General Electric
Image source: Visa. Let’s have a look at the quarterly reports from a few stocks in the news July 21.
Jul 19, 2017
Novartis’ Clinical Pipeline Continues to Innovate
Image Source: Novartis. We continue to be impressed with the depth of Novartis’ clinical pipeline, which should aid in the company’s acceleration from the revenue cliff experienced as a result of the patent loss of top-selling product Gleevec. We are adding Novartis to the portfolio of the Dividend Growth Newsletter.
Jul 18, 2017
Stocks in the News: Harley-Davidson, Johnson & Johnson, Netflix
Earnings season is picking up. Let’s evaluate a few quarterly reports from some bellwethers.
Jul 12, 2017
Important Valuentum Announcements
We have a few important announcements and a couple reminders to share.
Jul 12, 2017
Analyzing the S&P SPDR Biotech ETF
Source: S&P SPDR Biotech ETF (XBI). ETFs are rapidly becoming the preferred investment vehicle to gain broad exposure to a particular sector. The biotech industry is no different with two distinct ETFs dominating the niche. The article discusses the unique characteristics of the SPDR Biotech ETF to determine the merits of the idea.
Jul 11, 2017
Loxo Oncology Presents Compelling Data on Its TRK Inhibitors
Image Source: Loxo Oncology. The field of oncology remains an area of intense focus with a dire need for new novel therapies. Loxo Oncology generated lots of excitement with the release of its clinical data for Larotrectinib, a TRK-inhibitor for the treatment of a diverse number of tumors.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.